Arnd Jacobi

Summary

Country: Germany

Publications

  1. ncbi Infliximab in the treatment of moderate to severe atopic dermatitis
    Arnd Jacobi
    Department of Dermatology, University of Erlangen Nurnberg, Erlangen, Germany
    J Am Acad Dermatol 52:522-6. 2005
  2. ncbi Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study
    Arnd Jacobi
    Department of Dermatology, University Hospital Marburg, Marburg, Germany
    Dermatology 216:133-6. 2008
  3. ncbi [Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders]
    Arnd Jacobi

    J Dtsch Dermatol Ges 1:259-72. 2003

Detail Information

Publications3

  1. ncbi Infliximab in the treatment of moderate to severe atopic dermatitis
    Arnd Jacobi
    Department of Dermatology, University of Erlangen Nurnberg, Erlangen, Germany
    J Am Acad Dermatol 52:522-6. 2005
    ..Chronic use of standard therapies for atopic dermatitis (AD) is associated with variable efficacy and potential side effects. Targeted therapeutic approaches, such as the inhibition of tumor necrosis factor-alpha, may be a novel option...
  2. ncbi Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study
    Arnd Jacobi
    Department of Dermatology, University Hospital Marburg, Marburg, Germany
    Dermatology 216:133-6. 2008
    ..Facial psoriasis requires a treatment approach other than topical corticosteroids which bear the risk of skin atrophy. Topical pimecrolimus has been shown to be effective in atopic eczema and recently in psoriasis...
  3. ncbi [Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders]
    Arnd Jacobi

    J Dtsch Dermatol Ges 1:259-72. 2003
    ..Such guidelines are necessary to improve the efficacy of anticytokine treatment and to reduce side effects...